[Clinical evaluation of a new drug combination in the therapy of acute and chronic bronchopneumopathies].
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000996:Antitussive Agents / Q000008:administration & dosage*; D001982:Bronchial Diseases / Q000188:drug therapy*; D002233:Carbocysteine / Q000008:administration & dosage*; D002648:Child; D002908:Chronic Disease; D003545:Cysteine / Q000031:analogs & derivatives*; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008171:Lung Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010069:Oxadiazoles / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*
D000996:Antitussive Agents; D010069:Oxadiazoles; D010880:Piperidines; D002233:Carbocysteine; C008277:libexin; D003545:Cysteine
Valutazione clinica di una nuova associazione farmacologica nella terapia delle broncopneumopatie acute e croniche.